BioVaxys Technology Corp.
BVAXF
$0.0389
$0.00010.26%
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.84M | 1.49M | 1.51M | 1.69M | 1.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.81M | 1.49M | 1.52M | 1.79M | 1.83M |
| Operating Income | -1.81M | -1.49M | -1.52M | -1.79M | -1.83M |
| Income Before Tax | -3.58M | -4.83M | -5.53M | -6.63M | -10.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.58 | -4.83 | -5.53 | -6.63 | -10.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.58M | -4.83M | -5.53M | -6.63M | -10.35M |
| EBIT | -1.81M | -1.49M | -1.52M | -1.79M | -1.83M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.03 | -0.04 | -0.05 | -0.09 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.03 | -0.03 | -0.02 |
| EPS Diluted | -0.02 | -0.03 | -0.04 | -0.05 | -0.09 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.03 | -0.03 | -0.02 |
| Average Basic Shares Outstanding | 718.82M | 645.56M | 567.81M | 536.57M | 497.23M |
| Average Diluted Shares Outstanding | 718.82M | 645.56M | 567.81M | 536.57M | 497.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
